Dr. Reddy's inches up on launching generic version of Vimovo tablets in US market

28 Feb 2020 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 3081.00, up by 12.35 points or 0.40% from its previous closing of Rs. 3068.65 on the BSE.

The scrip opened at Rs. 3060.00 and has touched a high and low of Rs. 3081.00 and Rs. 3000.00 respectively. So far 7183 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 3260.00 and Rs. 3000.00 respectively. The current market cap of the company is Rs. 50995.47 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.

Dr. Reddy’s Laboratories has launched the first generic version of Vimovo tablets, used to treat rheumatoid arthritis, in the US market. The company announced the first-to-market launch of Naproxen and Esomeprazole Magnesium delayed-release tablets in the US market.

The company's product is the generic version of Vimovo tablets approved by the US Food and Drug Administration (USFDA).

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×